Comparative Pharmacology
Head-to-head clinical analysis: PROMAZINE HYDROCHLORIDE versus VESPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMAZINE HYDROCHLORIDE versus VESPRIN.
PROMAZINE HYDROCHLORIDE vs VESPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promazine hydrochloride is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, as well as histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors. It also has moderate serotonin and weak serotonin-dopamine antagonist effects.
Trifluoperazine is a typical antipsychotic that blocks postsynaptic D2 dopamine receptors in the mesolimbic pathway. It also has alpha-adrenergic blocking and anticholinergic effects.
25-50 mg intramuscularly every 4-6 hours as needed. Maximum 150 mg/day.
10-50 mg intramuscularly every 4-6 hours as needed; oral: 25-50 mg every 4-6 hours
None Documented
None Documented
Terminal elimination half-life: 12-18 hours; in elderly or hepatic impairment may extend to 30 hours
Terminal elimination half-life ranges from 1 to 2.5 hours, with a mean of approximately 1.5 hours. Due to its short half-life, multiple daily dosing is required to maintain therapeutic levels, and the drug is rapidly cleared after discontinuation.
Primarily renal (approx. 70-80% as metabolites, <1% unchanged); minor biliary/fecal (approx. 15-20%)
Primarily hepatic metabolism with metabolites excreted in urine and feces. Approximately 20-30% of a single dose is excreted unchanged in urine, with the remainder as metabolites in urine (30-40%) and feces (20-30%).
Category C
Category C
Antipsychotic
Antipsychotic